(E/Z)-AG490 | Tyrphostin B 42 | EGFR Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / (E/Z)-AG490

(E/Z)-AG490 {[allProObj[0].p_purity_real_show]}

货号：A603326 同义名： Tyrphostin B 42;(E/Z)-Tyrphostin AG490

(E/Z)-AG490是 AG490 的消旋体，其中 (E)-AG490 是一种酪氨酸激酶抑制剂，能够抑制 EGFR、Stat-3 及 JAK2/3 信号通路。该化合物在癌症研究中展示出显著的抑制肿瘤增殖和转移的潜力。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

(E/Z)-AG490 化学结构
CAS号：134036-52-5

(E/Z)-AG490 3D分子结构
CAS号：134036-52-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

(E/Z)-AG490 纯度/质量文件产品仅供科研

货号：A603326 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JACS Au, 2024. Ambeed. [ A148168 ]; • JMC, 2024. Ambeed. [ A187643 ]; • JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]; • Biomacromolecules, 2024. Ambeed. [ A110759 ]; • Biomacromolecules, 2024. Ambeed. [ A203543 ]; 更多 >

EGFR 亚型比较
STAT 亚型比较
JAK 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Daphnetin	+ EGFR, IC50: 7.67 μM					PKC,PKA	{[allProObj[0].p_purity_real_show]}
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		{[allProObj[0].p_purity_real_show]}
PD168393	++++ EGFR, IC50: 0.70 nM						{[allProObj[0].p_purity_real_show]}
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		{[allProObj[0].p_purity_real_show]}
Norcantharidin	✔						{[allProObj[0].p_purity_real_show]}
CL-387785	++++ EGFR, IC50: 370 pM						{[allProObj[0].p_purity_real_show]}
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	{[allProObj[0].p_purity_real_show]}
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	{[allProObj[0].p_purity_real_show]}
AG 555	+ EGFR, IC50: 0.7 μM						{[allProObj[0].p_purity_real_show]}
AG 494	+ EGFR, IC50: 1.2 μM						{[allProObj[0].p_purity_real_show]}
AG-556	+ EGFR, IC50: 5 μM						{[allProObj[0].p_purity_real_show]}
RG13022	+ EGFR, IC50: 4 μM						{[allProObj[0].p_purity_real_show]}
Tyrphostin RG 14620	✔						{[allProObj[0].p_purity_real_show]}
Vandetanib	+ EGFR, IC50: 500 nM						{[allProObj[0].p_purity_real_show]}
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		{[allProObj[0].p_purity_real_show]}
AZD3759	++++ EGFR (L858R), IC50: 0.2 nM EGFR (WT), IC50: 0.3 nM						{[allProObj[0].p_purity_real_show]}
Erlotinib	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Saracatinib	+++ EGFR, IC50: 5 nM EGFR (L861Q), IC50: 4 nM						{[allProObj[0].p_purity_real_show]}
AG1557	✔						{[allProObj[0].p_purity_real_show]}
Rociletinib	++ EGFR (L858R/T790M), Ki: 21.5 nM EGFR (wt), Ki: 303.3 nM						{[allProObj[0].p_purity_real_show]}
AG490	+ EGFR, IC50: 0.1 μM						{[allProObj[0].p_purity_real_show]}
Cetuximab	++++ EGFR, Kd: 0.39 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib	++ L858R/T790M EGFR, IC50: 11.44 nM WT EGFR, IC50: 12.92 nM						{[allProObj[0].p_purity_real_show]}
Osimertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Chrysophanol	✔					mTOR	{[allProObj[0].p_purity_real_show]}
PD153035	++++ EGFR, Ki: 5.2 pM						{[allProObj[0].p_purity_real_show]}
Olmutinib	✔					BTK	{[allProObj[0].p_purity_real_show]}
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						{[allProObj[0].p_purity_real_show]}
Icotinib	+++ EGFR, IC50: 5 nM						{[allProObj[0].p_purity_real_show]}
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						{[allProObj[0].p_purity_real_show]}
Cyasterone	✔						{[allProObj[0].p_purity_real_show]}
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						{[allProObj[0].p_purity_real_show]}
WZ8040	✔						{[allProObj[0].p_purity_real_show]}
(-)-Epigallocatechin Gallate	✔						{[allProObj[0].p_purity_real_show]}
AG 18	+ EGFR, IC50: 35 μM						{[allProObj[0].p_purity_real_show]}
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						{[allProObj[0].p_purity_real_show]}
Falnidamol	✔						{[allProObj[0].p_purity_real_show]}
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	{[allProObj[0].p_purity_real_show]}
Butein	✔						{[allProObj[0].p_purity_real_show]}
Genistein	✔						{[allProObj[0].p_purity_real_show]}
SU5214	+ EGFR, IC50: 36.7 μM						{[allProObj[0].p_purity_real_show]}
Naquotinib	✔						{[allProObj[0].p_purity_real_show]}
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		{[allProObj[0].p_purity_real_show]}
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		{[allProObj[0].p_purity_real_show]}
Lazertinib	++++ L858R/T790M EGFR, IC50: 2 nM WT EGFR, IC50: 76 nM				++++ Del19/T790M, IC50: 1.7 nM		{[allProObj[0].p_purity_real_show]}
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						{[allProObj[0].p_purity_real_show]}
MTX-211	✔					PI3K	{[allProObj[0].p_purity_real_show]}
(E)-AG 99	✔						{[allProObj[0].p_purity_real_show]}
Licochalcone D	✔					Caspase,PARP	{[allProObj[0].p_purity_real_show]}
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR(d746-750), IC50: 1.4 nM EGFR L858R, IC50: 2 nM		{[allProObj[0].p_purity_real_show]}
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		{[allProObj[0].p_purity_real_show]}
Firmonertinib mesylate	✔						{[allProObj[0].p_purity_real_show]}
Tyrphostin AG30	✔						{[allProObj[0].p_purity_real_show]}
EGFR-IN-12	++ EGFR, IC50: 21 nM						{[allProObj[0].p_purity_real_show]}
Mobocertinib	✔						{[allProObj[0].p_purity_real_show]}
(Rac)-JBJ-04-125-02	✔						{[allProObj[0].p_purity_real_show]}
(S)-Sunvozertinib	✔						{[allProObj[0].p_purity_real_show]}
BLU-945	✔						{[allProObj[0].p_purity_real_show]}
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			{[allProObj[0].p_purity_real_show]}
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			{[allProObj[0].p_purity_real_show]}
ARRY-380 analog				✔			{[allProObj[0].p_purity_real_show]}
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			{[allProObj[0].p_purity_real_show]}
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			{[allProObj[0].p_purity_real_show]}
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			{[allProObj[0].p_purity_real_show]}
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			{[allProObj[0].p_purity_real_show]}
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			{[allProObj[0].p_purity_real_show]}
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms	{[allProObj[0].p_purity_real_show]}
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^T790M, IC50: 0.79 nM EGFR^L858R/T790M, IC50: 0.51 nM		{[allProObj[0].p_purity_real_show]}
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	{[allProObj[0].p_purity_real_show]}
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			{[allProObj[0].p_purity_real_show]}
Tucatinib				+++ ErbB2, IC50: 8 nM			{[allProObj[0].p_purity_real_show]}
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Src,Raf	{[allProObj[0].p_purity_real_show]}
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			{[allProObj[0].p_purity_real_show]}
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	{[allProObj[0].p_purity_real_show]}
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			{[allProObj[0].p_purity_real_show]}
Afatinib dimaleate	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R/T790M), IC50: 0.4 nM			++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Canertinib dihydrochloride	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			{[allProObj[0].p_purity_real_show]}
Allitinib tosylate	++++ EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			{[allProObj[0].p_purity_real_show]}
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			{[allProObj[0].p_purity_real_show]}
Afatinib	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			{[allProObj[0].p_purity_real_show]}
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			{[allProObj[0].p_purity_real_show]}
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			{[allProObj[0].p_purity_real_show]}
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			{[allProObj[0].p_purity_real_show]}
ALK-IN-1					++ EGFR(C797S/del19), IC50: 138.6 nM EGFR(del19), IC50: 36.8 nM	ALK	{[allProObj[0].p_purity_real_show]}
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	ALK,FLT3	{[allProObj[0].p_purity_real_show]}
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	{[allProObj[0].p_purity_real_show]}
EAI045					✔		{[allProObj[0].p_purity_real_show]}
Almonertinib					✔		{[allProObj[0].p_purity_real_show]}
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		{[allProObj[0].p_purity_real_show]}
EGFR-IN-7					++++ EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM EGFR^L858R/T790M, IC50: 0.19 nM		{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	STAT1 ↓ ↑	STAT3 ↓ ↑	STAT5 ↓ ↑	纯度
Nifuroxazide	✔			{[allProObj[0].p_purity_real_show]}
Fludarabine	✔			{[allProObj[0].p_purity_real_show]}
Artesunate		✔		{[allProObj[0].p_purity_real_show]}
BP-1-102		+++ STAT3, Kd: 504 nM		{[allProObj[0].p_purity_real_show]}
Niclosamide		++ STAT3, IC50: 0.7 μM		{[allProObj[0].p_purity_real_show]}
Napabucasin		✔		{[allProObj[0].p_purity_real_show]}
Cryptotanshinone		++ STAT3, IC50: 4.6 μM		{[allProObj[0].p_purity_real_show]}
Stattic		+ STAT3, IC50: 5.1 μM		{[allProObj[0].p_purity_real_show]}
NSC 74859		+ STAT3, IC50: 86 μM		{[allProObj[0].p_purity_real_show]}
Ochromycinone		✔		{[allProObj[0].p_purity_real_show]}
HO-3867		✔		{[allProObj[0].p_purity_real_show]}
C188-9		++++ STAT3, Kd: 4.7 nM		{[allProObj[0].p_purity_real_show]}
HJC0152		✔		{[allProObj[0].p_purity_real_show]}
SH5-07		✔		{[allProObj[0].p_purity_real_show]}
SH-4-54		++++ STAT3, Kd: 300 nM	+++ STAT5, Kd: 464 nM	{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	JAK1 ↓ ↑	JAK2 ↓ ↑	JAK3 ↓ ↑	Tyk2 ↓ ↑	其他靶点	纯度
Decernotinib	+++ JAK1, IC50: 11 nM JAK1, Ki: 11 nM	+++ JAK2, Ki: 13 nM	++++ JAK3, Ki: 2.5 nM	+++ TYK2, Ki: 13 nM		{[allProObj[0].p_purity_real_show]}
ZM39923 HCl	+ JAK1, pIC50: 4.4		+ JAK3, pIC50: 7.1		EGFR	{[allProObj[0].p_purity_real_show]}
Cerdulatinib	+++ JAK1, IC50: 12 nM	+++ JAK2, IC50: 6 nM	+++ JAK3, IC50: 8 nM	++++ TYK2, IC50: 0.5 nM		{[allProObj[0].p_purity_real_show]}
Momelotinib	+++ JAK1, IC50: 11 nM	++ JAK2, IC50: 18 nM	+ JAK3, IC50: 155 nM			{[allProObj[0].p_purity_real_show]}
XL019	+ JAK1, IC50: 134.3 nM	++++ JAK2, IC50: 2.2 nM	+ JAK3, IC50: 214.2 nM		FLT3	{[allProObj[0].p_purity_real_show]}
Ruxolitinib	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM				{[allProObj[0].p_purity_real_show]}
Tofacitinib	+ JAK1, IC50: 112 nM	++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			{[allProObj[0].p_purity_real_show]}
Ruxolitinib (S enantiomer)	+++ JAK1, IC50: 3.3 nM	++++ JAK2, IC50: 2.8 nM		++ TYK2, IC50: 19 nM		{[allProObj[0].p_purity_real_show]}
Filgotinib	+++ JAK1, IC50: 10 nM	++ JAK2, IC50: 28 nM	+ JAK3, IC50: 810 nM	+ TYK2, IC50: 116 nM		{[allProObj[0].p_purity_real_show]}
Baricitinib	+++ JAK1, IC50: 5.9 nM	+++ JAK2, IC50: 5.7 nM		++ TYK2, IC50: 53 nM		{[allProObj[0].p_purity_real_show]}
Gandotinib	++ JAK1, IC50: 19.8 nM	++++ JAK2, IC50: 0.288 nM JAK2 (V617F), Ki: 0.245 nM	++ JAK3, IC50: 48.0 nM	++ TYK2, IC50: 44 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Oclacitinib maleate	+++ JAK1, IC50: 10nM	++ JAK2, IC50: 18nM	+ JAK3, IC50: 99nM	+ TYK2, IC50: 84nM		{[allProObj[0].p_purity_real_show]}
NVP-BSK805 2HCl	++ JAK1, IC50: 31.63 nM	++++ JAK2, IC50: ~0.5 nM	++ JAK3, IC50: 18.68 nM	+++ TYK2, IC50: 10.76 nM		{[allProObj[0].p_purity_real_show]}
Peficitinib		✔				{[allProObj[0].p_purity_real_show]}
Go6976		✔			FLT3	{[allProObj[0].p_purity_real_show]}
AZD-1480		++++ JAK2, IC50: 0.26 nM				{[allProObj[0].p_purity_real_show]}
Fedratinib		+++ JAK2, IC50: 3 nM JAK2 (V617F), IC50: 3 nM			RET,FLT3	{[allProObj[0].p_purity_real_show]}
WP1066		+ JAK2, IC50: 2.3 μM				{[allProObj[0].p_purity_real_show]}
Curcumol		✔				{[allProObj[0].p_purity_real_show]}
AZ960		++++ JAK2, IC50: <3 nM JAK2, Ki: 0.45 nM				{[allProObj[0].p_purity_real_show]}
GLPG0634 analog		✔				{[allProObj[0].p_purity_real_show]}
CEP-33779		++++ JAK2, IC50: 1.8 nM				{[allProObj[0].p_purity_real_show]}
FLLL32		+ JAK2, IC50: <5 μM				{[allProObj[0].p_purity_real_show]}
WHI-P154			+ JAK3, IC50: 1.8 μM		Src,VEGFR,EGFR	{[allProObj[0].p_purity_real_show]}
BMS-911543		++++ JAK2, IC50: 1.1 nM	+ JAK3, IC50: 75 nM	++ TYK2, IC50: 66 nM		{[allProObj[0].p_purity_real_show]}
TG101209		+++ JAK2, IC50: 6 nM	+ JAK3, IC50: 169 nM		RET,FLT3	{[allProObj[0].p_purity_real_show]}
AT9283		++++ JAK2, IC50: 1.2 nM	++++ JAK3, IC50: 1.1 nM			{[allProObj[0].p_purity_real_show]}
Pacritinib		++ JAK2, IC50: 23 nM JAK2 (V617F), IC50: 19 nM	+ JAK3, IC50: 520 nM	++ TYK2, IC50: 50 nM	FLT3	{[allProObj[0].p_purity_real_show]}
Tofacitinib citrate		++ JAK2, IC50: 20 nM	++++ JAK3, IC50: 1 nM			{[allProObj[0].p_purity_real_show]}
FM-381			++++ JAK3, IC50: 127 pM			{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

(E/Z)-AG490 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.40mL

0.68mL

0.34mL

16.99mL

3.40mL

1.70mL

33.98mL

6.80mL

3.40mL

(E/Z)-AG490 技术信息

CAS号	134036-52-5
分子式	C₁₇H₁₄N₂O₃
分子量	294.305

别名	Tyrphostin B 42;(E/Z)-Tyrphostin AG490;(E/Z)-Tyrphostin B42
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 105 mg/mL(356.77 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

(E/Z)-AG490 {[allProObj[0].p_purity_real_show]}

(E/Z)-AG490 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

(E/Z)-AG490 质控信息

(E/Z)-AG490 实验方案

(E/Z)-AG490 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

(E/Z)-AG490 {[allProObj[0].p_purity_real_show]}

(E/Z)-AG490 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

(E/Z)-AG490 质控信息

(E/Z)-AG490 实验方案

(E/Z)-AG490 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

(E/Z)-AG490 纯度/质量文件产品仅供科研